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oouth America is the fourth largest geographic
area in the world, with an estimated popula-
tion close to 380 million inhabitants distrib-
ted in its 12 countries. In most of the countries,
he population is quite heterogeneous in their so-
ioeconomic situation, and one can easily identify
n epidemiologic transition whereby the 3 levels of
eceding pandemics, degenerative and man-made
iseases, and delayed degenerative diseases patterns
re observed. Ischemic heart disease, stroke, hyper-
ensive heart disease, Chagas disease, and rheumatic
eart disease are, in this order, the likely causes of
ardiovascular mortality and disability in most of
hese countries.
The population size, cardiovascular mortality
ate, number of cardiologists in each national cardi-
logy society, and their scientific production as
btained from the World Health Organization
http://www.who.int/cardiovascular_diseases/
esources/atlas/en/), and the abstracts presented at
he American College of Cardiology meetings, are
hown in Table 1. They are an indication of the
nterest in yielding quality publications from these
ountries, and point toward the adequacy of steps
o be taken to further enhance this endeavor.
In the past years, interesting scientific articles
ave been published in local periodicals. We scru-
inized those journals and made a random selec-
ion from each of the South American countries
ith a regular, accessible publication of what
eemed to be outstanding original articles in the
ear 2006. ierna´ndez A, Ferrante D, Hrabar A, et al.
rognostic Value of the Body Mass Index
n Patients With Chronic Heart Failure:
he GESICA Registry. Rev Argent Cardiol
006;74:204–10
tudy Objective
his study sought to verify the possible prognostic
ole of body mass index (BMI) in the evolution of
atients with heart failure.
ethods
cohort of 2,331 adult ambulatory patients with
table ischemic or nonischemic heart failure of at least
months’ duration, included as of May 1999 in 64
ealth centers throughout Argentina (National Heart
ailure Registry, GESICA), was evaluated with a
ean follow-up of 957 days.
Heart failure was defined as the presence or history
f any of the following signs or symptoms that im-
roved with diuretics: dyspnea on exertion (not attrib-
table to any other cause) and/or paroxysmal noctur-
al dyspnea and/or acute pulmonary edema and/or
igns of systemic venous congestion. Patients with
eart failure caused by valvular or congenital disor-
ers, hypertrophic cardiomyopathy, or pericardial
isorders were excluded, as well as patients with severe
hronic comorbidities.
End points assessed were death and cause of death,
dmissions for decompensated heart failure, and ad-
issions for other causes.
A cutoff point of BMI was chosen based on the
ccurrence of events. The association between mortal-
ty and BMI was tested with univariate and multivari-
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From Around the World August 14, 2007:643–6te analyses, including potential confounding factors (Cox
egression).
esults
he population, according to BMI categories, was grouped
s follows: 20 kg/m2, 61 patients (2.61%); 20 to 24.99
g/m2, 668 patients (28.65%); 25 to 29.99 kg/m2, 999
atients (42.85%); and 30 kg/m2 or higher, 603 patients
25.86%). A higher BMI was related to less severe heart
ailure and lower mortality. A multivariate analysis showed:
MI 20 kg/m2: hazard ratio (HR) 1.72 (95% confidence
nterval [CI] 1.14 to 2.59, p  0.009), BMI 25 to 29.99
g/m2: HR 0.78 (95% CI 0.64 to 0.95, p  0.015), BMI
30 kg/m2: HR 0.79 (95% CI 0.63 to 0.99, p  0.047).
onclusions
he BMI provides additional prognostic information in am-
ulatory patients with HF. Its prognostic value is similar in
ifferent subgroups of patients according to left ventricular
unction, time from diagnosis, and comorbid conditions.
omments
his study presents additional evidence already pointed out in
he literature, mostly through retrospective analysis, about the
pparent paradoxical protective effect of obesity in the evolu-
ion of heart failure. Because obesity in itself is often identified
s a proinflammatory condition, this protective effect is hard
Table 1 Characteristics of Cardiovascular Disease and Reso
Countries
Population* (Millions)
2005
Age-Standardized Mortality
Rate by Cardiovascular
Causes (per 100,000
Population)†
Argentina 32.6 212
Bolivia 9.2 260
Brazil 186.4 341
Chile 16.3 165
Colombia 45.6 240
Ecuador 13.2 244
Guyana 0.7 526
Paraguay 6.2 291
Peru 28.0 190
Suriname 0.4 421
Uruguay 3.5 208
Venezuela 26.6 241
From World Development Indicators Database, April 2006. Available at: http://web.worldban
ttp://www.who.int/cardiovascular_diseases/en/cvd_atlas_29_world_data_table.pdf. §Numb
ardiologists in this country. ¶Estimated by local authorities.o believe if one considers that the obesity helps to defend bgainst the intensively activated inflammation that is docu-
ented in advanced cases of heart failure. In the future, pro-
pective studies with serial measurement of these cytokines will
elp to elucidate this phenomenon.
ilas-Boas F, Feitosa GS, Soares MBP, et al.
arly Results of Bone Marrow Cell
ransplantation to the Myocardium of Patients
ith Heart Failure Due to Chagas Disease.
rq Bras Cardiol 2006;87:159–66
tudy Objective
his study sought to evaluate feasibility, safety, and early
ffects of bone marrow cell transplantation to the myocar-
ium of patients with congestive heart failure caused by
hagas disease.
ethods
e studied 28 patients (mean age 52.2  9.9 years), of
hom 24 were male. Despite optimized treatment, 25 pa-
ients were in New York Heart Association (NYHA) func-
ional class III, and 3 patients were in NYHA functional
lass IV. The procedure consisted of aspiration of 50 ml of
one marrow, separation of the mononuclear fraction, and
ntracoronary injection. Effects on left ventricular ejection
raction, distance walked in the 6-min walking test, quality
f life, NYHA functional class, and arrhythmogenic and
in South America
er of Cardiologists
egistered in the
tional Societies
of Cardiology
Number of Publications
on Cardiovascular
Diseases
(1991–2001)‡
Number of Abstracts
Presented at the
American College of
Cardiology Annual
Scientific Session
(2000–2006)
3,600§ 110 39
110 — —
11,000 307 145
254 53 3
899 11 2
65 3 —
— — —
111 1 —
330 3 —
— — —
120¶ 2 —
170¶ — 2
World Health Statistics. Available at: http://www.who.int/topics/mortality/en/. ‡Available at:
ll members of the Argentine Society of Cardiology. There is an estimation of more than 7,000urces
Numb
R
Na
k.org. †iochemical parameters were all evaluated.
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here were no complications directly related to the procedure.
aseline left ventricular ejection fraction was 20.1 6.8%,
nd 60 days after transplantation it increased to 23.0 9.0%,
 0.02. Significant improvements were observed in the
YHA functional class (3.1 0.3 to 1.8 0.5, p 0.0001);
uality of life (50.9 11.7 to 21.8 13.4, p 0.0001), and
istance walked in 6 min (355 136 m to 443 110 m, p
0,003). The number of ventricular premature beats in 24 h
ended to increase (5,322 4,977 to 7,441 7,955, p
.062), but without increase in ventricular tachycardia epi-
odes (61 127 to 54 127, p 0.27).
onclusions
ur data show for the first time that intracoronary injec-
ion of bone marrow mononuclear cells is feasible and sug-
est that it may be potentially safe and effective in patients
ith congestive heart failure caused by Chagas disease.
omments
his pilot study is very relevant and explores a new form of
herapy for patients with heart disease. It is the first study in
his area that deals with Chagas heart disease. This condition is
till prevalent in South America, where there is an estimation
f more than 20 million people affected, and some 5 million
xpected to develop heart disease, out of which 1 million will
ave its severest form, which presents a very poor prognosis
ith the currently established treatment for heart failure. This
tudy originated a much larger National Health Department-
unded multicenter, randomized, double-blind, placebo-con-
rolled study to determine the efficacy of this method, and has
lready been launched in Brazil.
ira MT, Kunstmann S, Guarda E, Villarroel L.
ccuracy of the Self Report Method for
stablishing the Prevalence of Cardiovascular
isk Factors in Healthy Adults: Results of
he RICAR Project. Rev Chil Cardiol
006;25:191–7
tudy Objective
his study sought to determine in a healthy adult population
he accuracy of their self-reported normal or abnormal values
f blood pressure (BP), total cholesterol (TC), and blood sugar
BS), compared with clinical findings.
ethods
questionnaire about their own BP, TC, and BS was an-wered by 12,190 healthy adults from the RICAR Project pRiesgo Cardiovascular, de la Sociedad Chilena de Cardio-
ogı´a) (6,320 women and 5,870 men, mean age 47.6  12
ears). Those who knew their parameters (BP, n  2,430;
C, n  1,163; BS, n  1,556) were asked if they had
ormal or abnormal values. Using standardized methods,
e measured systolic blood pressure (SBP) and diastolic
lood pressure (DBP), TC, and BS and compared the re-
erred data of normality/abnormality with clinical findings.
esults
he SBP and DBP were respectively incorrectly reported as
ormal in 18.2% and 15.6% of the population. For TC
nd BS, the mistaken reported normal values were 44.9%
nd 15.8% respectively. Women had significantly more
ccurate self-reported normal values than men for SBP,
BP, and BS: 84.3% versus 77.6%; 88.7% versus 77%,
nd 97.5% versus 94%, respectively (p  0.0001), al-
hough they had a significantly lower education level than
en. Positive predictive values for abnormal SBP, DBP,
C, and BS were 54.3%, 46.7%, 75.1%, and 41.8%, re-
pectively. Negative predictive values for the same parame-
ers were 81.7%, 84.4%, 55.1%, and 96.4%, respectively.
rue versus apparent prevalences showed differences with
n overestimation of systolic hypertension 30% versus
2.6%, diastolic hypertension 25.7% versus 32.6%, and
igh BS 10% versus 16.7%. Kappa index was low among
hese methods.
onclusions
nowledge of their own BP, TC, and BS were suboptimal
n this population. Self-report induced a significant differ-
nce between true and apparent prevalence of cardiovascu-
ar risk factors. These results show the unreliability of self-
eported data to establish accurate cardiovascular risk
actors prevalence in this population.
omments
his important study clearly shows the need for local evalu-
tion of most of the scientific observations, especially for
hose who deal with less easily verifiable variables, such as is
ften is the case in population studies, to surpass educa-
ional and cultural differences. Self-reported data have been
sed in some large health surveys in the United States and
urope, and some of those reports might influence impor-
ant decisions regarding public health. Even in those places,
he validity of the methods has been questioned. The
resent study shows that for the fundamental variables that
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opulation, reliability is not adequate.
ierra-Laguado J, Garcı´a RG, Celedo´n J, et al.
nsulin Resistance Index Assessment by HOMA
nd Its Relation With the Risk of Pregnancy-
nduced Hypertension. Rev Col Cardiol
006;12:459–65
tudy Objective
his study sought to assess whether insulin resistance deter-
ined by homeostatic model assessment (HOMA) is an
arly predictor of the development of pregnancy-induced
ypertension in Colombian pregnant women.
ethods
his was a nested case control study in a prospective cohort
f 438 normotensive primigravidae women with gestational
ge 30 weeks. The HOMA was calculated using fasting
lasma concentrations of glucose and insulin, determined
y glucose-oxidase and chemoluminescence methods,
espectively.
esults
wenty-three pregnant women developed pregnancy-
nduced hypertension (5.25%). Two normotensive preg-
ant women were selected as controls for each case,
atched by gestational and maternal age at enrollment.
he women who subsequently developed pregnancy-
nduced hypertension had higher levels of HOMA (1.48 
.98 vs. 0.96  0.70, p  0.001), which was associated
ith an increased risk of developing pregnancy-induced
ypertension (odds ratio 3.8, 95% CI 1.1 to 12.8, p 
.01). Systolic blood pressure levels at enrollment were
ignificantly higher in pregnant women who later devel-
ped pregnancy-induced hypertension (106  12 vs. 97 
0, p  0.01), showing an interaction with the levels of
OMA in the multiple logistic regression model.
onclusions
omen who subsequently developed pregnancy-induced
ypertension were more insulin resistant before the onset of
linical manifestations of the disease. The HOMA index
ould be a useful tool for screening women at risk of devel-
ping pregnancy-induced hypertension.
omments
he mechanisms involved in the development of pregnancy-
nduced hypertension have not yet been fully elucidated, noras a simple method that reliably will predict its development
een established. The HOMA should eventually be tested
gainst other methods to evaluate its comparative performance
egarding reliability and cost effectiveness.
aggio V, Espero´n P, Lorenzo M, et al. CYP2C9
nd Apolipoprotein E Variants and Individual
esponse to Warfarin. Rev Urug Cardiol
006;21:104–16
tudy Objective
his study sought to examine the influence of the genetic
ariants of CYP2C9 and apolipoprotein E (ApoE) on inter-
ndividual variability in response to warfarin and the risk of
dverse reactions in an Uruguayan population.
ethods
he study involved 55 patients undergoing chronic oral
nticoagulant treatment with warfarin. Data on daily main-
enance dose, pharmacokinetic response, and adverse reac-
ions were collected. The CYP2C9*1, *2, and *3, and
poE E2, E3, and E4 genotype were determined by stan-
ard procedures.
esults
arriers of CYP2C9*3 allele required the lesser mainte-
ance dose, followed by CYP2C9*2 allele carriers and then
YP2C9*1 homozygotes (p  0.049). The CYP2C9*3
llele carriers had more episodes above the range of the
nternational Normalized Ratio and required more dose
djustments to achieve a proper anticoagulation; adverse
vents were more frequent in patients with CYP2C9*1/*3
egarding bleeding events as wells as overanticoagulation.
resence of ApoE E4 allele is associated with a moderately
levated sensitivity to warfarin.
onclusions
his study is the first carried out on this subject in an Uru-
uayan population, and confirms an increased sensibility
o warfarin and risk of adverse effects in carriers of the
YP2C9*3 allele and in carriers of ApoE E4 variant, which
ould be useful in warfarin dose and risk individualization
uring treatment with this drug.
omments
here is a steadily increasing amount of evidence that
oints toward a future of better individualization of phar-
acologic treatment based on pharmacogenetics.doi:10.1016/j.jacc.2007.04.061
